Efecto renoprotector de los IECA, ARA II y su combinación en niños con síndrome nefrótico, Hospital del Niño Dr. Francisco De Icaza Bustamante, período enero 2019 a diciembre 2023.

Abstract

Background: nephrotic syndrome in children is a significant clinical condition that requires effective treatments to prevent kidney complications. The renoprotective effect of ACEI and ARA II has been investigated in this group of patients, but the evidence still requires greater clarity and updating. Materials and Methods: a study was carried out at the Francisco De Icaza Bustamante children's hospital between January 2019 and December 2023. Pediatric patients with nephrotic syndrome treated with ACEI, ARA II or double therapy were included... Results: a predominance of the male sex was observed (51.28%) and a higher incidence of diagnosis in children from 2 to 6 years (70.09%), without HTA. The majority of patients (88,89%) were corticosteroid-sensitive, while only (1.71%) relapsed frequently. Antiproteinuric treatment ACEI I was significantly associated with steroid reduction. The effectiveness of ACEI, ARBs and their combination in reducing proteinuria was evaluated. ACEIs showed the greatest effectiveness, with 47 of 48 patients achieving a significant reduction in proteinuria, followed by ARA II and the combination of both drugs (30 of 31 patients). The statistical results indicated a strong association between antiproteinuric treatment and the reduction of proteinuria (p=<0,001). Renal function remained stable in all patients. Conclusions: ACEIs and ARBs are effective options as adjuvants in reducing proteinuria and the dose of steroids in children with nephrotic syndrome.